These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 2272716)

  • 1. Pharmacokinetics of triflusal after single and repeated doses in man.
    Ramis J; Torrent J; Mis R; Conte L; Barbanoj MJ; Jané J; Forn J
    Int J Clin Pharmacol Ther Toxicol; 1990 Aug; 28(8):344-9. PubMed ID: 2272716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of triflusal and its main metabolite HTB in healthy subjects following a single oral dose.
    Ramis J; Mis R; Forn J; Torrent J; Gorina E; Jané F
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):269-73. PubMed ID: 1823870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bioequivalence of two oral formulations of triflusal capsules in healthy volunteers.
    Quetglas EG; Campanero MA; Sádaba B; Escolar M; Azanza JR
    Arzneimittelforschung; 2008; 58(6):283-7. PubMed ID: 18677970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of triflusal and its main metabolite in rats and dogs.
    Ramis J; Mis R; Forn J
    Eur J Drug Metab Pharmacokinet; 1991; 16(4):261-8. PubMed ID: 1823869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Binding of a metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic acid) to serum proteins in rat and man.
    Mis R; Ramis J; Conte L; Forn J
    Eur J Clin Pharmacol; 1992; 42(2):175-9. PubMed ID: 1618249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Platelet antiaggregatory effect of triflusal in human whole blood.
    de la Cruz JP; Pavia J; Bellido I; González MC; Sánchez de la Cuesta F
    Methods Find Exp Clin Pharmacol; 1988 Apr; 10(4):273-7. PubMed ID: 3386335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of food on the pharmacokinetics of triflusal and its major active metabolite, 2-hydroxy-4-trifluoromethyl benzoic acid, in healthy subjects.
    Ge J; Ding LK; Yang J; Jia YY; Lu CT; Ding Y; Song Y; Song W; Wen AD
    Int J Clin Pharmacol Ther; 2015 Mar; 53(3):272-6. PubMed ID: 25546165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study to characterize the multiple-dose pharmacokinetics, pharmacodynamics and safety of new enteric-coated triflusal formulations in healthy male volunteers.
    Lee HW; Lim MS; Seong SJ; Lee J; Park J; Seo JJ; Yun HY; Baek IH; Kwon KI; Yoon YR
    Expert Opin Drug Metab Toxicol; 2011 Dec; 7(12):1471-9. PubMed ID: 22098139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics, safety and tolerability of triflusal and its main active metabolite HTB in healthy Chinese subjects.
    Wang M; Zhang Q; Huang M; Zong S; Hua W; Zhou W
    Drug Res (Stuttg); 2014 May; 64(5):263-8. PubMed ID: 24105106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-trifluoromethylbenzoic acid.
    Fernández de Arriba A; Cavalcanti F; Miralles A; Bayón Y; Alonso A; Merlos M; García-Rafanell J; Forn J
    Mol Pharmacol; 1999 Apr; 55(4):753-60. PubMed ID: 10101034
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of fosfosal after single and multiple oral doses in man.
    Ramis J; Torrent J; Mis R; Barbanoj M; Abadias M; Jane F; Forn J
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):421-7. PubMed ID: 3264273
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.
    Park SM; Lee J; Seong SJ; Park JG; Gwon MR; Lim MS; Lee HW; Yoon YR; Yang DH; Kwon KI; Han S
    BMC Pharmacol Toxicol; 2014 Dec; 15():75. PubMed ID: 25534747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary pharmacokinetic study of ibuprofen enantiomers after administration of a new oral formulation (ibuprofen arginine) to healthy male volunteers.
    Fornasini G; Monti N; Brogin G; Gallina M; Eandi M; Persiani S; Bani M; Della Pepa C; Zara G; Strolin Benedetti M
    Chirality; 1997; 9(3):297-302. PubMed ID: 9176996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Access of HTB, main metabolite of triflusal, to cerebrospinal fluid in healthy volunteers.
    Valle M; Barbanoj MJ; Donner A; Izquierdo I; Herranz U; Klein N; Eichler HG; Müller M; Brunner M
    Eur J Clin Pharmacol; 2005 Apr; 61(2):103-11. PubMed ID: 15711832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 4-trifluoromethyl derivatives of salicylate, triflusal and its main metabolite 2-hydroxy-4-trifluoromethylbenzoic acid, are potent inhibitors of nuclear factor kappaB activation.
    Bayón Y; Alonso A; Sánchez Crespo M
    Br J Pharmacol; 1999 Mar; 126(6):1359-66. PubMed ID: 10217529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of triflusal and acetylsalicylic acid on platelet aggregation in human whole blood: influence of red blood cells and leukocytes.
    de la Cruz JP; Pavia J; Bellido I; Sánchez de la Cuesta F
    Methods Find Exp Clin Pharmacol; 1988 Jun; 10(6):363-7. PubMed ID: 3412046
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of duloxetine hydrochloride enteric-coated tablets in healthy Chinese volunteers: a randomized, open-label, single- and multiple-dose study.
    Zhao RK; Cheng G; Tang J; Song J; Peng WX
    Clin Ther; 2009 May; 31(5):1022-36. PubMed ID: 19539103
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of clopidogrel.
    Caplain H; Donat F; Gaud C; Necciari J
    Semin Thromb Hemost; 1999; 25 Suppl 2():25-8. PubMed ID: 10440419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus.
    von Nicolai H; Brickl R; Eschey H; Greischel A; Heinzel G; König E; Limmer J; Rupprecht E
    Arzneimittelforschung; 1997 Mar; 47(3):247-52. PubMed ID: 9105542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The pharmacokinetic behavior of AWD 26-06 in humans following single and multiple administration].
    Terhaag B; Richter K; Feller K
    Pharmazie; 1992 Jan; 47(1):43-5. PubMed ID: 1608984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.